RxDoctor Payments Data

Kevin Brown, MD

Internal Medicine · Springfield, ORNPI 1558757922

Payments from drug & device makers

$2,242in general payments, 2019–2025

Across 128 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$354
  • Novo Nordisk$336
  • AstraZeneca$315
  • GSK$211
  • Lilly USA, LLC$176
  • Corium, LLC$166
  • plus $686 from 11 others

What the payments were for

  • Food & beverage$2,22499%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,242 in reported general payments places this provider in the 90th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$55,168
Medicare patients
140
Services billed
1,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$59,401
MounjaroTirzepatide16$40,936
FarxigaDapagliflozin Propanediol23$33,654
RybelsusSemaglutide22$31,639
JanuviaSitagliptin Phosphate17$30,217
EliquisApixaban32$29,754
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$7,397
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,880
SymbicortBudesonide/Formoterol Fumarate18$4,637
Breo ElliptaFluticasone/Vilanterol12$4,612
Nano 2nd Gen Pen NeedlePen Needle, Diabetic31$2,493
Gabapentin181$2,114
Varenicline Tartrate11$2,028
Clonidine14$1,978
Albuterol Sulfate HfaAlbuterol Sulfate69$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$336$91,04175 claims
Lilly USA, LLCMounjaro$176$40,93616 claims
AstraZenecaFarxiga, Symbicort$315$38,29141 claims
GSKBreo Ellipta$211$4,61212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →